Autolus Therapeutics (AUTL) Equity Average (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Equity Average data on file, last reported at $221.8 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 50.95% year-over-year to $221.8 million; the trailing twelve-month figure through Dec 2025 stood at $221.8 million (down 50.95% YoY), and the FY2025 full-year result was $302.7 million, up 12.37% from the prior year.
• Equity Average for Q4 2025 stood at $221.8 million, down from $306.0 million in the prior quarter.
• Across five years, Equity Average topped out at $554.9 million in Q2 2024 and bottomed at $146.0 million in Q4 2023.
• The 5-year median for Equity Average is $280.9 million (2021), against an average of $303.3 million.
• The widest annual swing landed in 2024, when Equity Average soared 209.7%; it then plunged 50.95% in 2025.
• A 5-year view of Equity Average shows it stood at $279.0 million in 2021, then decreased by 17.6% to $229.9 million in 2022, then tumbled by 36.5% to $146.0 million in 2023, then jumped by 209.7% to $452.1 million in 2024, then slumped by 50.95% to $221.8 million in 2025.
• The last three Equity Average figures came in at $221.8 million (Q4 2025), $306.0 million (Q3 2025), and $358.8 million (Q2 2025), per Business Quant data.

Peer Comparison